Pfizer Inc and its German partner BioNTech said on Thursday
PHOTO
Pfizer Inc and its German partner BioNTech said on Thursday that their Omicron-adapted COVID-19 vaccine booster generated a strong immune response against the currently circulating BA.5 and the BA.4 subvariants of Omicron.
The companies said data from a trial in adult patients showed that the booster dose showed a substantial increase in neutralizing antibody levels against the BA.4/BA.5 variants. (Reporting by Manas Mishra in Bengaluru; Editing by Savio D'Souza)
Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.
© ZAWYA 2024
